Skip to main content
. 2024 Mar 13;6(1):e000544. doi: 10.1136/bmjno-2023-000544

Table 2.

Disproportionality analysis by drug

Drug ROR 95% CI (p<0.001) % GBS over other events
Avelumab 29.854 14.8 to 58.9 0.57
Atezolizumab 17.075 12.5 to 23.1 0.32
Ipilimumab 16.084 12.4 to 20.8 0.30
Pembrolizumab 11.977 9.4 to 15.1 0.22
Nivolumab 8.218 6.3 to 10.6 0.15

.GBS, Guillain-Barré syndrome; ROR, reporting OR.